<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48716">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02072928</url>
  </required_header>
  <id_info>
    <org_study_id>MAF/AGN/NS/OAB/005</org_study_id>
    <nct_id>NCT02072928</nct_id>
  </id_info>
  <brief_title>Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the  impact of BOTOX® treatment on anticholinergic drug use in
      patients with urinary incontinence from Neurogenic Detrusor Overactivity (NDO) due to spinal
      injury or Multiple Sclerosis (MS) who are prescribed BOTOX® as standard of care in clinical
      practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <primary_outcome>
    <measure>Reduction in Anticholinergic Drug Use</measure>
    <time_frame>Baseline, 9 Months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>BOTOX®</arm_group_label>
    <description>Patients with incontinence from NDO due to spinal injury or MS prescribed BOTOX® (Botulinum toxin Type A) as standard of care in clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>botulinum toxin Type A</intervention_name>
    <description>botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.</description>
    <arm_group_label>BOTOX®</arm_group_label>
    <other_name>onabotulinumtoxinA</other_name>
    <other_name>BOTOX®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with incontinence from NDO due to spinal injury or MS treated as per standard of
        care in clinical practice.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients prescribed BOTOX® for urine incontinence from NDO due to spinal injury or MS
             as standard of care in clinical practice in Belgium

          -  Previous treatment with anticholinergic drugs ineffective

          -  Last BOTOX® treatment ≥18 months.

        Exclusion Criteria:

          -  Diagnosis of urinary incontinence less than 9 months.

          -  No anticholinergic drug use in the last 9 months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Allergan Inc.</last_name>
    <email>clinicaltrials@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Esneux</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 25, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Incontinence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
